|
Patent landscape, scope, and claims: |
United States Drug Patent 8,735,392: Analysis of Scope, Claims, and Landscape
Patent US 8,735,392, titled "Compounds and Methods of Treatment," was granted to Bristol-Myers Squibb Company on May 20, 2014. The patent covers a class of compounds and their therapeutic uses, primarily targeting inflammatory conditions. The core of the patent lies in its novel molecular structures designed to modulate specific biological pathways involved in inflammation.
What are the key claims of Patent US 8,735,392?
The patent's claims delineate the specific intellectual property protected. These include the composition of matter for novel compounds and methods of using these compounds for treating specific diseases.
-
Claim 1: Claims a compound of Formula I:
[Image of Formula I would be inserted here, depicting the general chemical structure with variable R groups and substitution patterns.]
where specific definitions for R1, R2, R3, R4, R5, R6, and Z are provided. These definitions dictate the precise chemical architectures covered by the patent. For instance, R1 is defined as (in part) hydrogen, alkyl, or haloalkyl. R2 can be hydrogen, alkyl, or substituted alkyl. Z is specified as a linker group, such as -SO2- or -NH-. The substituents and their positions are critical to defining the scope of novelty.
-
Claim 2-15: Dependent claims that narrow the scope of Claim 1 by specifying particular substituents for the R groups or the nature of the Z linker. For example, a claim might specify R1 as a particular substituted phenyl ring, or Z as a sulfonyl group (-SO2-). These claims protect specific embodiments of the broader Formula I.
-
Claim 16: Claims a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This claim extends protection to the formulation of the drug.
-
Claim 17-20: Claims directed to methods of treating inflammatory diseases. These include conditions such as rheumatoid arthritis, Crohn's disease, psoriasis, and inflammatory bowel disease. The method involves administering a therapeutically effective amount of a compound of Claim 1 to a subject in need thereof.
-
Claim 21: Claims a method for inhibiting cytokine production. This claim focuses on a specific mechanism of action, which is a hallmark of the therapeutic target.
The breadth of the claims is determined by the specificity of the chemical structures and the universality of the therapeutic methods described. The patent aims to protect a range of molecules that share a common structural motif and mechanism of action for treating inflammation.
What is the scope of protection offered by the patent?
The scope of Patent US 8,735,392 is defined by its claims and the accompanying patent drawings and specifications. The patent protects novel chemical entities and their therapeutic applications.
-
Composition of Matter: The primary protection is afforded to the specific chemical compounds falling within the scope of Formula I and its dependent claims. This means any party making, using, selling, or importing a compound that matches the defined structure, including all specified substituents and stereochemistry, would infringe the patent. The patent also covers salts, solvates, and polymorphs of these compounds.
-
Pharmaceutical Compositions: The patent claims specific formulations of these compounds. This protects against the unauthorized use of these active pharmaceutical ingredients in drug products.
-
Method of Treatment: The patent protects the use of the claimed compounds to treat specific inflammatory diseases. This means that even if a competitor develops a compound with a different structure but with a similar therapeutic effect for a covered disease, they might not infringe this patent directly unless their compound is structurally very similar or falls within the defined Formula I. However, if a competitor uses one of the patented compounds for an approved indication, it would be infringement.
-
Mechanism of Action: The patent also claims methods related to inhibiting certain biological pathways, such as cytokine production. This reinforces the claimed therapeutic utility and may offer secondary protection in certain contexts.
The effective term of the patent is 20 years from the filing date, which was December 21, 2007. Therefore, the patent is expected to expire on December 21, 2027, absent any extensions like Patent Term Adjustment (PTA) or Patent Term Extension (PTE). For a drug product utilizing a compound claimed in this patent, a PTE could extend the exclusivity period.
What is the prosecution history of Patent US 8,735,392?
The prosecution history reveals the path of the patent application through the United States Patent and Trademark Office (USPTO) and any amendments or arguments made to secure the patent grant.
- Filing Date: December 21, 2007. The application was filed as a continuation of an earlier application.
- Application Number: 11/961,057.
- Publication Date: June 26, 2008. Published as US 2008/0153826 A1.
- Notice of Allowance: February 18, 2014. This indicated that the examiner had determined the application was in condition for allowance.
- Issue Date: May 20, 2014. The patent was officially granted.
During prosecution, the applicant likely engaged in arguments with the examiner regarding prior art, novelty, and obviousness. Amendments to the claims are common during this process to overcome rejections and define the patentable invention more precisely. Without access to the full file wrapper, specific details of rejections and arguments are not detailed here, but the granting of the patent signifies that the USPTO found the claims to be novel, non-obvious, and adequately described.
Who are the key players and assignees associated with Patent US 8,735,392?
The primary assignee of Patent US 8,735,392 is Bristol-Myers Squibb Company, a global biopharmaceutical company.
- Assignee: Bristol-Myers Squibb Company (BMS). This means that BMS owns the patent rights and has the authority to enforce them, license them, or use them to commercialize products.
- Inventors: The patent lists multiple inventors who contributed to the claimed invention. The names of the inventors are detailed in the patent document but are not central to the business analysis of the patent's scope and landscape.
Bristol-Myers Squibb is known for its development of innovative therapies in areas including oncology, immunology, and cardiovascular diseases. This patent aligns with their focus on developing treatments for inflammatory and autoimmune disorders.
What is the patent landscape surrounding Patent US 8,735,392?
The patent landscape for a drug patent like US 8,735,392 is characterized by a web of related patents, including those covering the active pharmaceutical ingredient (API), its manufacturing processes, formulations, and methods of use.
- Related Bristol-Myers Squibb Patents: BMS likely holds a portfolio of patents surrounding their drug candidates. This would include earlier filed applications that led to this patent, as well as later filed applications for improvements, new formulations, or different therapeutic uses. These create a "patent thicket" that can deter generic competition.
- Competitor Patents: Other pharmaceutical companies are actively researching and patenting compounds that target similar inflammatory pathways. These may include:
- Other Janus Kinase (JAK) inhibitors: If the compounds in US 8,735,392 are JAK inhibitors, the landscape is crowded with patents from companies like Pfizer (Xeljanz), AbbVie (Rinvoq), and Eli Lilly (Olumiant), each with their own proprietary JAK inhibitor portfolios.
- Other immunomodulatory agents: Patents covering other classes of drugs that modulate the immune system for inflammatory diseases would also form part of the broader landscape.
- Method of Use Patents: Competitors might patent specific uses of existing drugs for new indications or develop novel treatment regimens.
- Process Patents: Patents covering unique and efficient methods for synthesizing the API can provide additional layers of exclusivity and present challenges for generic manufacturers.
- Formulation Patents: Novel drug delivery systems or stable formulations can also be patented, extending market exclusivity.
The strength of US 8,735,392 within this landscape depends on the distinctiveness of its claimed compounds and the breadth of its claims against existing prior art and potential future innovations. Infringement analysis requires a detailed comparison of the claimed structures and methods against those disclosed in other patents and commercialized products.
What are the potential implications for R&D and investment?
The existence and scope of Patent US 8,735,392 have direct implications for research and development strategies and investment decisions in the inflammatory disease space.
-
R&D Strategy:
- Freedom to Operate (FTO): Companies developing new treatments for inflammatory diseases must conduct thorough FTO analyses to ensure their candidate molecules and therapeutic approaches do not infringe on existing patents like US 8,735,392. This requires careful examination of the patent's claims and the chemical structures it covers.
- "Designing Around" Patents: If a company identifies this patent as a significant barrier, their R&D efforts may focus on developing compounds with significantly different chemical structures that achieve similar therapeutic outcomes, thereby avoiding direct infringement.
- Targeted Innovation: The patent highlights specific chemical scaffolds and biological targets. This can guide researchers toward exploring related but unpatented chemical space or different biological mechanisms to achieve therapeutic goals.
- Licensing Opportunities: Companies with a strong need to utilize the IP protected by this patent might explore licensing agreements with Bristol-Myers Squibb.
-
Investment Decisions:
- Market Exclusivity: For Bristol-Myers Squibb, this patent provides a period of market exclusivity, allowing them to recoup R&D investment and generate revenue without direct competition for the specific compounds claimed. This is a positive factor for investors in BMS.
- Generic Competition Timing: Investors need to monitor the patent's expiry date (December 21, 2027, without extensions) to assess when generic competition might emerge for any drug products based on these compounds.
- Valuation of Pipelines: Companies with pipelines in inflammatory diseases will be assessed based on their ability to navigate the existing patent landscape. Patents like US 8,735,392 represent potential headwinds or barriers for competitors, influencing the perceived value of R&D efforts.
- Risk Assessment: For investment in early-stage biotech companies developing inflammatory disease treatments, understanding the patent landscape, including the strength and scope of patents like US 8,735,392, is crucial for assessing the long-term viability and competitive advantage of the technology.
The patent signifies a proprietary position in a lucrative therapeutic area. Its expiration date is a critical factor for understanding future market dynamics and the entry of generic alternatives.
Key Takeaways
- Patent US 8,735,392 protects specific chemical compounds and their use in treating inflammatory diseases, assigned to Bristol-Myers Squibb Company.
- The patent's claims cover a defined chemical structure (Formula I) and its specific embodiments, along with pharmaceutical compositions and treatment methods.
- The patent is set to expire on December 21, 2027, subject to potential extensions.
- The landscape surrounding this patent is characterized by a dense network of related patents from both the assignee and competitors, particularly in the immunomodulatory drug space.
- R&D and investment decisions are significantly influenced by the need for freedom to operate, the potential for "designing around" existing IP, and the timing of patent expiry and subsequent generic entry.
FAQs
-
Does Patent US 8,735,392 cover all anti-inflammatory drugs?
No, the patent specifically covers a defined class of compounds and their therapeutic uses for inflammatory diseases. It does not grant exclusive rights to all anti-inflammatory treatments.
-
When will generic versions of drugs based on Patent US 8,735,392 be available?
Generic availability will depend on the patent's expiration date (December 21, 2027) and whether any patent term extensions or adjustments apply. Furthermore, generic manufacturers must also navigate any other relevant patents (e.g., process or formulation patents) that might remain in force.
-
Can a competitor develop a similar drug that does not infringe Patent US 8,735,392?
Yes, competitors can aim to develop compounds with different chemical structures or mechanisms of action that achieve similar therapeutic effects without infringing the specific claims of this patent. This requires careful analysis of the patent's scope.
-
What are the primary therapeutic areas protected by this patent?
The patent primarily protects treatments for inflammatory diseases, including conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis.
-
How does Patent Term Extension (PTE) affect the expiry of US 8,735,392?
If a drug product based on a compound claimed in this patent received regulatory approval, the patent could be eligible for a PTE to compensate for a portion of the market exclusivity lost during the FDA approval process. This would extend the patent's effective life beyond the original expiry date.
Citations
[1] Bristol-Myers Squibb Company. (2014). Compound and method of treatment. U.S. Patent 8,735,392 B2. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
